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The aim of this study was to investigate the frequency and mutation status of the immunoglobulin heavy variable chain (IGHV)
in a cohort of 224 patients from northwest and central region of Spain diagnosed with chronic lymphocytic leukemia (CLL), and
to correlate it with cytogenetic abnormalities, overall survival (OS) and time to first treatment (TTFT). 125 patients had mutated
IGHV, while 99 had unmutated IGHV. The most frequently used IGHV family was IGHV3, followed by IGHV1 and IGHV4. The
regions IGHV3-30, IGHV1-69, IGHV3-23, and IGHV4-34 were the most commonly used. Only 3.1% of the patients belonged to
the subfamily IGHV3-21 and we failed to demonstrate a worse clinical outcome in this subgroup.The IGHV4 family appearedmore
frequentlywithmutated pattern, similar to IGHV3-23 and IGHV3-74. By contrast, IGHV1-69was expressed at a higher frequency in
unmutatedCLL patients. All the cases from IGHV3-11 and almost all from IGHV5-51 subfamily belonged to the group of unmutated
CLL.
1. Introduction
Chronic lymphocytic leukemia (CLL) is a clinically and bio-
logically heterogeneous disease, with survival times ranging
from months to decades [1, 2]. Rai and Binet staging systems
were designed to provide prognostic information, and are
widely used in clinical practice [3, 4]. However, some patients
with early stages rapidly progress.
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Over the past decade, several biological markers have
become important prognostic factors and may guide treat-
ment decisions. These include immunoglobulin heavy chain
variable region (IGHV) mutation status, expression of spe-
cific proteins on CLL cells such as CD38 and intracellular
zeta-associated protein-70 (ZAP-70), and some cytogenetic
abnormalities [5–9].
Clonal genomic aberrations can be identified in approxi-
mately 80% of CLL patients by fluorescence in situ hybridiza-
tion (FISH). Usually, patients with deletion of chromosome
13q14 as a single alteration have a better outcome, although a
high number of losses in 13q14 or large deletions including
RB1 gene could be associated with a worse outcome [10].
By contrast, patients with deletion of chromosome 11q22
or chromosome 17p13 show a shorter OS, while cases with
trisomy 12 have an intermediate prognosis [7, 11].
The IGHVgenemutation status is one of themost reliable
prognostic markers. It defines two different subsets of CLL
based on the cutoff value of 98% identity with the closest
germ line IGHV genes: mutated CLL (M-CLL) and unmu-
tated CLL (U-CLL). Somatic mutations of IGHV occur in
approximately half of the cases and usually present with non-
progressive disease, in contrast to patients with U-CLL who
have amore aggressive diseasewith a shorter progression-free
survival, time to first treatment (TTFT), and overall survival
(OS) [11, 12]. Furthermore, irrespective of mutation status,
some heavy chain variable regions have been associated
with specific clinical features and varying occurrences from
country to country. For example, IGHV1-69 gene has been
observed to be one of the most frequently rearranged genes
in Western patients and is almost always associated with
the subset of U-CLL [13]. Other subgroups reported to be
frequently used in Western patients are IGHV3-23, IGHV4-
34, and IGHV3-07. Moreover, an overrepresentation of the
IGHV3-21 gene has been reported in northern European
countries compared to the Mediterranean region, and it has
been associated with a worse prognosis despite the mutation
status [13, 14].
In this study, we investigated the frequency and mutation
status of IGHV in a cohort of patients from northwest and
central region of Spain. We also analyzed the relationship
between IGHV mutation status and some other CLL prog-
nostic markers such as the expression of CD38, cytogenetic
abnormalities detected by FISH, OS, and TTFT.
2. Patients, Materials, and Methods
2.1. Patients. A total of 224 unselected patients diagnosed
with typical CLL from nine different institutions located
in northwest and central region of Spain were studied for
IGHV gene usage and mutation status. The diagnosis was
based on clinical symptoms, immunophenotypic analysis,
blood cell count, and cell morphology, according to the
World Health Organization classification of tumors [15] and
National Cancer Institute guidelines [16]. The study was
approved by the local ethics committee and all individuals
provided their informed consent. The median age of the
patients was 63 years (range, 29–90 years). A hundred
and fifty-two patients were male (68%) and seventy-two
(32%) were female (male/female ratio = 2.1). At the time
of diagnosis, most cases were classified as stage A (77%)
according to Binet classification [4].
2.2. Sample Processing and DNA Extraction. Mononuclear
cells were isolated using Ficoll density gradient centrifugation
from peripheral blood samples containing more than 10% of
CLL cells determined by flow cytometry. Genomic DNA was
extracted and purified, washed, and lysed according to the
manufacturer’s instructions using the DNAzol kit (Molecular
Research Center, Cincinnati, OH, USA).
2.3. PCR Amplification of IgH Rearrangements. IGHV gene
rearrangements were amplified by reverse transcription-
PCR according to ERIC recommendations [17], using a
mixture of 5󸀠 primers specific for framework region (FR) 1
consensus family (IGHV1-IGHV6), together with 3󸀠 primers
complementary to the germ line JH regions. All samples were
tested for the amplification of IGH rearrangements according
to the BIOMED-2 Concerted Action protocols in whose
standardization our group has participated actively [18]. In
this strategy, complete V-D-J rearrangement amplification
was performed by multiplex PCR with a set of family-
specific primers of the framework region (FR1) and one IGHJ
consensus primer. When amplification was unsuccessful, a
second PCR was performed with primers from the IGHV
leader region. In all cases amplification consisted of an initial
denaturation step of 10 minutes at 95∘C followed by 35 cycles
of 94∘C, 60∘C, and 72∘C for 30 seconds each, with a final
extension step of 30 minutes at 72∘C.
2.4. Sequencing of PCR Products. Clonality was assessed by
size discrimination of PCR products using automatic ABI
3130 Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA) in conjunctionwithGeneMapper 4.0 software (Applied
Biosystems). To purify amplified products, they were run
on 8% polyacrylamide gel, heteroduplexed in cases with
polyclonal background, and visualized by ethidium bromide
staining. Purified PCR products were then eluted from
polyacrylamide gel and sequencingwas performed fromboth
directions, at least from 2 PCR reactions, using the BigDye
Terminator v1.1 Cycle Sequencing Reaction Kit (Applied
Biosystems) on an automated DNA Sequencer analyzer (ABI
3130, Applied Biosystems).
2.5. Analysis of IG Gene Sequences. The obtained sequen-
ces were aligned to V-Base (http://www2.mrc-lmb.cam.ac
.uk/vbase/list2.php) data base. IGHV sequences with <98%
homology with respect to the germ line counterpart were
considered as mutated, while those with an identity greater
than or equal to 98% were considered as unmutated. The
cutoff value of 96%was also contemplated in order to analyze
differences with possible prognostic interest.
2.6. FISH Analysis. Interphase FISH was performed on
peripheral blood samples obtained at diagnosis using com-
mercially available probes for the following regions: 13q14;
12q13; 11q22/ATM; 17pTP53; and 14q32/IGH (Vysis/Abbott
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Figure 1: IGHV gene segments usage profile of patients with M-CLL and patients with U-CLL (number of cases).
Co., Downers Grove, IL, USA). Methods for FISH analysis
are described elsewhere [19]. The sensitivity limit for the
detection of 14q32 translocation, trisomy 12, and deletions
was >3%, >3%, and >8% interphase cells with split signal,
three signals, and one signal, respectively. Dual color FISH
using differently labeled control probes was performed, and
signal screeningwas carried out on at least 200 cells withwell-
delineated signals. Hybridization was repeated in those slides
with less than 80% cells showing tow control-probe signals.
2.7. CD38 Expression. CD38 expression was analyzed by 4-
colour fluorescence—activated cell sorting (FACS) analysis.
For data analysis, the Infinicyt software (Cytognos SL, Sala-
manca, Spain) was used [20].
2.8. Statistical Analysis. Statistical analysis was performed
using the SPSS 17.0 software package (SPSS, Chicago, IL,
USA). The Fischer’s exact test and the Chi-squared test
were used to determine the relationship between categorical
variables. Quantitative variables were compared by using the
Student’s t-test and the Mann-Whitney U test. OS was cal-
culated from the time of diagnosis to death or last follow-up
visit. TTFT was calculated as the interval between diagnosis
and the start of first line treatment. OS and TTFT were
estimated by the Kaplan-Meier method and assessed by the
log-rank test. Statistical significance was defined as 𝑃 < 0.05.
3. Results
3.1. IGHV Mutation Status. We analyzed mutation status
of 224 patients with CLL. Based on a cutoff value of 98%
nucleotide sequence homology of isolated IGHV gene with
that of the germ line counterpart, a total of 125 (55.8%) cases
were classified as M-CLL and 99 (44.2%) patients as U-CLL.
When we considered 96% as the cutoff value, 102 (45.6%)
cases displayed somatic mutations, whereas 124 (54.4%) were
unmutated.
3.2. IGHV Gene Family Usage and Mutation Status. IGHV
gene usage was identified in 216 patients.Themost frequently
used IGHV family was IGHV3: 107 (49.5%), followed by
IGHV1: 55 (25.5%), IGHV4: 41 (19.0%), IGHV5: 8 (3.7%),
IGHV2: 3 (1.4%), and IGHV7: 2 (0.9%), with no expression of
IGHV6. Mutation status (≥98% homology) and its relation-
ship with sex and IGHV rearrangements are summarized in
Table 1.
IGHV3 and IGHV4 regions were found predominantly
in the M-CLL cases (72/107, 𝑃 = 0.004, and 30/41, 𝑃 =
0.022, resp.) in contrast to IGHV1 genes, which were found
predominantly in the U-CLL cases (37/55, 𝑃 = 0.0001). Only
3.2% of patients used IGHV5 regions, and 7 out of 8 cases
displayed unmutated status (𝑃 = 0.023).
Among IGHV1 family, IGHV1-69 was also preferentially
expressed in U-CLL (18 versus 3 cases 𝑃 < 0.0001).
Regarding IGHV3 family, IGHV3-30 was the most com-
mon region used (20.6%), followed by IGHV3-23 (19%),
with a low representation of IGHV3-7 (4.0%) and IGHV3-21
(3.2%). IGHV3-21 and IGHV3-7 expressed a mutated status
in all but one case. Both IGHV3-23 (𝑃 < 0.0001) and IGHV3-
74 (𝑃 = 0.018) presented more frequently the mutated
pattern. By contrast, the five patientswith IGHV3-11 belonged
to the subgroup of U-CLL (𝑃 = 0.016). Interestingly,
within IGHV5 family, IGHV5-51 genes appeared to bemostly
unmutated (𝑃 = 0.016). Figure 1 shows IGHV gene segment
usage profile of patients with M-CLL and patients with U-
CLL.
3.3. Association of Mutation Status and Rearranged IGHV
Genes withDisease Outcome. Patients withU-CLL seemed to
have a more aggressive disease. Despite establishing homol-
ogy in 98 or 96%, U-CLL patients presented with a higher
4 BioMed Research International
Table 1: Mutation status (≥98% homology) and its relationship with IGHV rearrangements and sex.
IGHV family Mutated cases Unmutated cases Mutated and unmutated % 𝑃 Male/female
IGHV1 2 5 7 3.2 ns 4/3
IGHV1-02 3 7 10 4.6 ns 5/5
IGHV1-03 2 2 4 1.9 ns 0/4
IGHV1-08 3 2 5 2.3 ns 3/2
IGHV1-18 2 2 4 1.9 ns 4/0
IGHV1-46 3 1 4 1.9 ns 3/1
IGHV1-69 3 18 21 9.7 <0.0001 15/6
Total IGHV1 18 37 55 25.5 <0.0001 34/21
IGHV2-01 1 0 1 0.5 ns 0/1
IGHV2-05 0 1 1 0.5 ns 0/1
IGHV2-70 0 1 1 0.5 ns 1/0
Total IGHV2 1 2 3 1.4 ns 1/2
IGHV3 3 2 5 2.3 ns 3/2
IGHV3-07 8 1 9 4.0 ns 9/0
IGHV3-09 2 2 4 1.9 ns 2/2
IGHV3-11 0 5 5 2.3 0.016 4/1
IGHV3-13 1 2 3 1.4 ns 3/0
IGHV3-15 4 2 6 2.8 ns 2/4
IGHV3-20 1 1 2 0.9 ns 1/1
IGHV3-21 6 1 7 3.2 ns 5/2
IGHV3-23 18 1 19 8.8 <0.0001 12/7
IGHV3-30 12 10 22 10.0 ns 17/5
IGHV3-33 4 3 7 3.2 ns 5/2
IGHV3-48 1 2 3 1.4 ns 3/0
IGHV3-49 2 2 4 1.9 ns 1/3
IGHV3-53 1 0 1 0.5 ns 1/0
IGHV3-64 0 1 1 0.5 ns 1/0
IGHV3-72 2 0 2 0.9 ns 2/0
IGHV3-74 7 0 7 3.2 0.018 5/2
Total IGHV3 72 35 107 49.5 0.004 85/22, P = 0.088
IGHV4-b 2 2 4 1.9 ns 1/3
IGHV4-04 5 0 5 2.3 0.051 3/2
IGHV4-30 1 1 2 0.9 ns 1/1
IGHV4-31 0 1 1 0.5 ns 1/0
IGHV4-34 14 4 18 8.3 ns 11/7
IGHV4-39 3 3 6 2.8 ns 3/3
IGHV4-59 2 0 2 0.9 ns 1/1
IGHV4-61 3 0 3 1.4 ns 2/1
Total IGHV4 30 11 41 19 0.022 23/18
IGHV5-05 0 1 1 0.5 ns 1/0
IGHV5-51 1 6 7 3.2 0.046 7/0
Total IGHV5 1 7 8 3.7 0.023 8/0, P = 0.05
IGHV7-04 0 2 2 0.9 ns 0/2
Total IGHV7 0 2 2 0.9 ns 0/2
initial white blood cell count (WBC) (median 31.5 × 109/L
versus 21.2 × 109/L; 𝑃 = 0.038) and higher levels of LDH
(𝑃 = 0.003), belonged to advanced Binet stages (𝑃 = 0.001),
progressed more frequently (𝑃 < 0.0001), and had a shorter
leukocyte duplication time (𝑃 = 0.001). Diffuse pattern of
bone marrow infiltration and secondary tumors (𝑃 = 0.047)
were also more often observed in this subgroup of patients.
The estimated median OS of the group with 98% or
greater IGHVhomology was 215months, while the estimated
median OS time of the subgroup with IGHV homology
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Figure 2: Kaplan-Meier survival curve comparing OS and TTFT
between patients with M-CLL (125 cases) and U-CLL (99 cases).
(a) Median OS for U-CLL: 117 months; median OS for M-CLL 215
months.The difference is significant at the 𝑃 = 0.027 level (log-rank
test). (b) Median TTFT for U-CLL: 29 months; median TTFT for
M-CLL: 227 months. The difference is significant at the 𝑃 = 0.0001
level (log-rank test).
less than 98% was 117 months (𝑃 = 0.027) (Figure 2(a)).
Comparison of TTFT betweenM-CLL andU-CLL revealed a
significantly higher TTFT in M-CLL versus U-CLL (227 and
29 months, resp., 𝑃 < 0.0001) (Figure 2(b)).
Regarding subfamily usage, it is noteworthy that patients
with IGHV1-69 had a higher probability to be treated (𝑃 =
0.002) and developed more frequently secondary neoplasms
(𝑃 = 0.005). By contrast, patients with IGHV3-07 were
associated with a lower WBC count (𝑃 = 0.001), male sex
(𝑃 = 0.03), and nonprogressive disease (𝑃 = 0.043). IGHV3-
30 usage was associated with normal levels of LDH (𝑃 =
0.005). Patients expressing IGHV3-11 subfamily had poor or
intermediate prognosis cytogenetic alterations in all cases but
one including 17p deletion in two patients, l1q deletion in one
patient, and trisomy 12 in two other patients.
We failed to correlate the use of IGHV3-21 region with
any feature, probably due to the low representation of this
subfamily.
Finally, it is remarkable that all patients who expressed
IGHV5-51 were males (𝑃 = 0.048), presented more fre-
quently with positive direct antiglobulin test (𝑃 = 0.028), and
Table 2: Relationship between genomic aberrations, CD38, and
mutation status.
FISH Mutation status
M-CLL U-CLL 𝑃
11q deletion Present 4 17 0.0001
Absent 121 82
13q deletion Present 61 20 0.0001
Absent 64 79
17p deletion Present 0 10 0.0001
Absent 126 88
12q trisomy Present 10 22 0.0003
Absent 115 77
CD38∗ Present 20 36 0.0001
Absent 46 19
∗Performed in 121 patients.
six out of seven showed cytogenetic aberrations including 11q
deletion (2 cases), trisomy 12 (2 cases), and 14q32 transloca-
tion (1 case).
OS was significantly worse in patients expressing IGHV1-
69 (𝑃 = 0.021) and IGHV3-11 (𝑃 = 0.025). Significantly
differences in prognosis could not be found in other IGHV
subgroups, including IGHV5-51 (𝑃 = 0.057). Regarding
patients using IGHV4 family, they had a significantly higher
TTFT (𝑃 = 0.001), with no cases of Richter syndrome
in patients with IGHV4-39. Only 29/103 patients expressing
IGHV3 received treatment (𝑃 = 0.016); albeit patients from
subfamily IGHV3-21 showed a tendency to be treated earlier.
On the other hand, 6/7 cases from family IGHV5 required
treatment during followup (𝑃 = 0.001).
3.4. Genomic Aberrations, CD38, and Mutation Status.
Patients with 13q deletion belonged significantly more fre-
quently to the mutated group (𝑃 = 0.005). By contrast,
high-risk aberrations such as 11q and 17p deletions were
significantly associated with the unmutated group (𝑃 = 0.003
and 𝑃 = 0.007, resp.). Patients with 12q trisomy were also
associated with the unmutated group (𝑃 = 0.003). No
relationship between patients without genomic aberrations
and mutation status was observed (Table 2).
Data for the expression of CD38 was available for 121
patients. Fifty-six patients were CD38 positive and 65 were
negative at a cutoff level for CD38 of 30%. A significant
different expression of CD38 between patients with M-CLL
(20) and those with U-CLL (36) was observed (𝑃 = 0.0001)
(Table 2).
4. Discussion
In patients with CLL, the presence of a correlation between
unmutated IGHV status and poor survival has been well
established in several studies [7–9]. This has led to extensive
investigations on the mutational status and IGHV gene usage
in different populations of patients diagnosed with CLL over
the last few years. Results from these studies suggest that
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the presence of ethnic variations and geographic background
may affect IGHV gene usage, in CLL [21–25].
The aim of our study was to investigate the frequency and
mutation status of IGHV in a cohort of 224 patients from
northwest and central region of Spain and to correlate it with
cytogenetic abnormalities, CD38 expression, OS, and TTFT.
We found 56% cases of M-CLL and 44% of U-CLL
when we established homology cutoff value on 98%. These
findings are consistent with previous publications inWestern
countries [9, 12, 24]. Our data also confirmed that patients
with unmutated IGHV genes had a distinctlymoremalignant
disease and much shorter OS and TTFT than those with
somatic mutations.
IGHV gene usage family distribution was also compa-
rable to those observed in Western countries [26], which
showed a higher representation of the IGHV3 family followed
by IGHV1 and IGHV4 (48.4%, 24.9%, and 18.6%, resp.).
With regard to the IGHV3 family, IGHV3-30 was the
most frequently used segment followed by IGHV3-23. By
contrast, IGHV3-7 was present in a relatively low frequency
(4%) and was seen preferentially in M-CLL (8/9). Similar
observations have been reported previously inMediterranean
countries and Serbian patients [12, 24, 27].
IGHV3-21 has been reported to be overrepresented in
Scandinavian patients with a lower frequency in Southern
European countries and has been associated with poor
prognosis independent of mutational status [27, 28]. We only
found 3.2% of the cases with this gene usage and 6 out of
7 belonged to the subgroup of M-CLL. Anyway, probably
due to the underrepresentation of this gene, we could not
see a worse clinical outcome in these patients, although a
trend to a shorter TTFT was observed (𝑃 = 0.07). Studies
from Asia [21, 22], South America [23], and Europe [12, 26]
showed a low representation of IGHV3-11 subfamily, with a
similar proportion of M-CLL and U-CLL in this subgroup.
However, the Ukrainian group showed that its presence was
associated with an increased risk of developing autoimmune
hemolytic anemia [25]. Interestingly, in our cohort, IGHV3-11
gene was significantly overused in the unmutated group and
was associated with a lower OS (𝑃 = 0.025), but we failed to
find a relationship with the risk of developing autoimmune
hemolytic anemia. Further study of larger series needs to be
performed to validate this data.
IGHV1-69 is the most frequently used gene in IGHV1
gene family of Western populations, exhibiting in most of
the cases a germ line profile [29] and, consequently, a more
aggressive disease. The higher usage of IGHV1-69 has been
reported in Ukrainian [25] and Mediterranean [12] CLL
patients. In accordance with these observations, IGHV1-69
was also the most frequently used segment of IGHV1 family
in our studied population and the second most commonly
detected in the global series (21 cases, 9.4%). We could also
confirm the association of IGHV1-69 with U-CLL cases, as 18
of our 21 cases had the unmutated profile (𝑃 < 0.0001), with
a significant worse OS (𝑃 = 0.021).
IGHV4 family has been reported to be overused in
the mutated subgroup of CLL [26]. In keeping with these
findings, we confirmed the significantly preferential use of
IGHV4 family in M-CLL (𝑃 = 0.02) and the consequently
better outcome of this subgroup with a longer TTFT (𝑃 =
0.001). IGHV4-34 had previously been reported to be among
the most frequently used genes in CLL rearrangements [12].
In our cohort, IGHV4-34 was used in 8.3% of the patients,
similar to previously described in Mediterranean patients
[30].
Regarding the remaining genes, we found a low rep-
resentation of IGHV5, IGHV2, and IGHV7 gene families
and lack of expression of IGHV6, as also described in other
studies, regardless of their ethnic origin [23]. However, it is
remarkable that, within the IGHV5 family, IGHV5-51 was
used in 8 patients (3.2%); all of themweremale and presented
with a shorter TTFT (𝑃 = 0.01). We could not confirm that
these patients had a worse prognosis, probably due to its low
representation. Further series including more patients with
this subfamily should be studied in the future to clarify these
findings. The Serbian cohort [24] and the Mediterranean
cohort [12] are the ones with more representation of this
subfamily and showed only 2% of this usage. Contrary to
our findings, they did not find differences in prognosis and
mutation status in this subgroup, probably due to the low
representation of this usage. Nevertheless, further studies of
larger series need to be performed.
Del(13q), del(11q), +12, del(17p), and IGH rearrangement
have been proved to be the most common and prognosti-
cally relevant chromosomal changes in CLL. As previously
reported [9], we confirmed that del(13q) was the most
prevalent genetic abnormality and was found more often in
patients with M-CLL, confirming its more favorable clinical
outcome. Our data also showed an association between high-
risk aberrations del(11q), +12, and del(17p) andU-CLL, which
is consistent with their poor clinical outcome [31].
CD38 has also been reported as an independent predictor
of prognosis for CLL, and its high expression has been cor-
related to unfavorable outcomes. It is controversial whether
high levels of CD38 expression may be used as a surrogate
marker of mutation status [22]. However, in our study we
found an association of CD38 and U-CLL.
5. Conclusions
Our data confirm that IGHV mutation status is one of the
most significant molecular predictors for CLL prognosis.The
identification of IGHV gene segments can provide additional
information regarding clinical course of CLL. The use of
IGHV3-21 had a low incidence in our series. IGHV3-11
identified a group of patients with poor prognosis. IGHV5-51
revealed a group of patients with a trend to a worse outcome.
In addition, OS and TTFTwere significantly related to IGHV
mutation status. Further studies of larger series, preferably in
the context of prospective clinical trials, need to be performed
to validate our data.
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